News

This article explains why reproducible conjugation methods are critical to antibody-drug conjugate development, supporting consistent efficacy, safety, regulatory compliance, and manufacturing efficiency.

Rapid antibody screening can help identify stronger antibody candidates earlier in immunoassay development. Fleet supports antibody screening across lateral flow, ELISA, Gyrolab™ and other assay formats, with small-volume screening approaches and in-house bioconjugation capability to support better assay decisions.

This article compares sandwich vs competitive assays in ELISA and lateral flow, focusing on format selection, reagent strategy and assay development considerations.

Lyophilisation can improve the stability and shelf life of diagnostic reagents. This article explores the key factors involved in optimising freeze-drying protocols, from formulation and freezing through to drying, packaging and stability testing.

Bioconjugation is transforming modern medicine by enabling targeted drug delivery and more precise therapeutic interventions. This article outlines how bioconjugation supports applications such as nanoparticles, polymer-drug conjugates, peptide conjugates, and antibody-drug conjugates to improve efficacy, specificity, and safety.

Outsourcing bioconjugation and antibody labelling can help life science and diagnostic organisations access specialist expertise, improve efficiency, reduce costs, and accelerate product development.

Ensuring the accuracy and reproducibility of ligand binding assays depends on high quality critical reagents, including antibodies and proteins. Fleet Bioprocessing Ltd. combines expert bioconjugation chemistry with a robust protein purification service to deliver highly purified reagents that meet rigorous assay standards.